Institution
Research Triangle Park
Nonprofit•Durham, North Carolina, United States•
About: Research Triangle Park is a nonprofit organization based out in Durham, North Carolina, United States. It is known for research contribution in the topics: Population & Environmental exposure. The organization has 24961 authors who have published 35800 publications receiving 1684504 citations. The organization is also known as: RTP.
Topics: Population, Environmental exposure, Receptor, Poison control, Agonist
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, a review of permeation-barrier technologies as well as the current status of thin-film permeation barriers for organic light-emitting devices (OLEDs) is provided.
Abstract: One of the advantages of organic light-emitting devices (OLEDs) over other display technologies is the ability to fabricate them on flexible substrates. As polymer substrates do not offer the same barrier performance as glass, OLEDs on polymer substrates will require thin-film barriers on both the bottom and top side of the device layers for sufficient lifetimes. This article provides a review of permeation-barrier technologies as well as the current status of thin-film permeation barriers for OLEDs. Topics include the implications of various device structures, permeation rate measurement, background and state-of-the-art of barrier technology, and mechanical and optical considerations for effective barriers.
528 citations
••
TL;DR: As the concentrations of M1 in the serum of pregnant rats and their pups on Postnatal Day 3 meet or exceed the in vitro Ki for androgen receptor inhibition, it is suggested that the demasculinizing effects of vinclozolin exposure in vivo also may be mediated via the antiandrogenic metabolites M1 and/or M2.
527 citations
••
TL;DR: In chronic angina patients, ranolazine monotherapy was well tolerated and increased exercise performance throughout its dosing interval at all doses studied without clinically meaningful hemodynamic effects.
526 citations
••
TL;DR: A single target-site mutation in the AHAS gene may confer tolerance to AHAS-inhibiting herbicides, so that it is technically possible to develop the imidazolinone-tolerance trait in many crops.
Abstract: Imidazolinone herbicides, which include imazapyr, imazapic, imazethapyr, imazamox, imazamethabenz and imazaquin, control weeds by inhibiting the enzyme acetohydroxyacid synthase (AHAS), also called acetolactate synthase (ALS). AHAS is a critical enzyme for the biosynthesis of branched-chain amino acids in plants. Several variant AHAS genes conferring imidazolinone tolerance were discovered in plants through mutagenesis and selection, and were used to create imidazolinone-tolerant maize (Zea mays L), wheat (Triticum aestivum L), rice (Oryza sativa L), oilseed rape (Brassica napus L) and sunflower (Helianthus annuus L). These crops were developed using conventional breeding methods and commercialized as Clearfield* crops from 1992 to the present. Imidazolinone herbicides control a broad spectrum of grass and broadleaf weeds in imidazolinone-tolerant crops, including weeds that are closely related to the crop itself and some key parasitic weeds. Imidazolinone-tolerant crops may also prevent rotational crop injury and injury caused by interaction between AHAS-inhibiting herbicides and insecticides. A single target-site mutation in the AHAS gene may confer tolerance to AHAS-inhibiting herbicides, so that it is technically possible to develop the imidazolinone-tolerance trait in many crops. Activities are currently directed toward the continued improvement of imidazolinone tolerance and development of new Clearfield* crops. Management of herbicide-resistant weeds and gene flow from crops to weeds are issues that must be considered with the development of any herbicide-resistant crop. Thus extensive stewardship programs have been developed to address these issues for Clearfield* crops.
525 citations
••
TL;DR: It is concluded that ambient air particles are capable of inducing a mild inflammation in the lower respiratory tract, as well as an increased concentration of blood fibrinogen.
Abstract: We tested the hypothesis that exposure of healthy volunteers to concentrated ambient particles (CAPS) is associated with an influx of inflammatory cells into the lower respiratory tract. Thirty-eight volunteers were exposed to either filtered air or particles concentrated from the immediate environment of the Environmental Protection Agency (EPA) Human Studies Facility in Chapel Hill, North Carolina. Particle concentrations in the chamber during the exposures ranged from 23.1 to 311.1 microgram/m(3). While in the exposure chamber, volunteers alternated between moderate exercise (15 min) and rest (15 min) for a total exposure time of 2 h. There were no symptoms noted by volunteers after the exposure. Similarly, there were no decrements in pulmonary function. Eighteen hours after exposure, analysis of cells and fluid obtained by bronchoalveolar lavage showed a mild increase in neutrophils in both the bronchial and alveolar fractions in those individuals exposed to CAPS (8.44 +/- 1.99 and 4.20 +/- 1.69%, respectively, in those with the greatest exposure) relative to filtered air (2.69 +/- 0.55 and 0.75 +/- 0.28%, respectively). Blood obtained 18 h after exposure to CAPS contained significantly more fibrinogen relative to samples obtained before exposure. We conclude that ambient air particles are capable of inducing a mild inflammation in the lower respiratory tract, as well as an increased concentration of blood fibrinogen.
525 citations
Authors
Showing all 25006 results
Name | H-index | Papers | Citations |
---|---|---|---|
Douglas G. Altman | 253 | 1001 | 680344 |
Lewis C. Cantley | 196 | 748 | 169037 |
Ronald Klein | 194 | 1305 | 149140 |
Daniel J. Jacob | 162 | 656 | 76530 |
Christopher P. Cannon | 151 | 1118 | 108906 |
James B. Meigs | 147 | 574 | 115899 |
Lawrence Corey | 146 | 773 | 78105 |
Jeremy K. Nicholson | 141 | 773 | 80275 |
Paul M. Matthews | 140 | 617 | 88802 |
Herbert Y. Meltzer | 137 | 1148 | 81371 |
Charles J. Yeo | 136 | 672 | 76424 |
Benjamin F. Cravatt | 131 | 666 | 61932 |
Timothy R. Billiar | 131 | 838 | 66133 |
Peter Brown | 129 | 908 | 68853 |
King K. Holmes | 124 | 606 | 56192 |